34th week of 2014 patent applcation highlights part 43 |
Patent application number | Title | Published |
20140234317 | METHODS FOR PREVENTING TOXIC DRUG-DRUG INTERACTIONS IN COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided. | 2014-08-21 |
20140234318 | TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF - The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer. | 2014-08-21 |
20140234319 | TREATMENT OF HEART FAILURE AND RELATED CONDITIONS - Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFβ1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFβ1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGFβ1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin. | 2014-08-21 |
20140234320 | MODULATORS OF 4-1BB AND IMMUNE RESPONSES - The invention provides peptides and fragments, methods and uses based upon modulating the binding or interaction between 4-1BB and galectins such as Galectin-9. Modulating such binding or interaction between 4-1BB and a galectin, such as Galectin 9. modulates an immune response. | 2014-08-21 |
20140234321 | HUNK, A SNF1-RELATED KINASE ESSENTIAL FOR MAMMARY TUMOR METASTASIS - This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the role of HUNK in tumor metastasis, primary tumor development, and the prediction of tumor behavior. | 2014-08-21 |
20140234322 | THROMBOPOIETIN MIMETICS FOR THE TREATMENT OF RADIATION OR CHEMICAL INDUCED BONE MARROW INJURY - Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor. | 2014-08-21 |
20140234323 | COMPOSITIONS AND METHODS FOR DETECTING TLR3 - The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects. | 2014-08-21 |
20140234324 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 2014-08-21 |
20140234325 | ADJUVANT THERAPY FOR STAPHYLOCOCCAL INFECTION WITH ENTEROTOXIN SPECIFIC MABS - Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID NO:30); ARTAGLLAPMDY (SEQ ID NO:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID NO:32) or VRDL YGDYVGRY A Y (SEQ ID NO:48). | 2014-08-21 |
20140234326 | METHOD FOR DECREASING RADIORESISTANCE AND GROWTH, METASTASIS AND INFILTRATION OF CANCER CELLS THROUGH REGULATING EXPRESSION OR ACTIVITY OF TM4SF4 IN NON-SMALL CELL LUNG CANCER - The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma. | 2014-08-21 |
20140234327 | MONOCLONAL ANTIBODY AGAINST HUMAN NON-SMALL CELL LUNG CARCINOMA AND USE THEREOF - The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma. | 2014-08-21 |
20140234328 | USE OF C-MET PROTEIN FOR PREDICTING THE EFFICACY OF ANTI-HEPATOCYTE GROWTH FACTOR ("HGF") ANTIBODIES IN ESOPHAGEAL AND GASTRIC CANCER PATIENTS - The present invention relates to use of the human Met receptor (also known as “c-Met”) for predicting the efficacy of inhibitors of the HGF-Met pathway, and in particular, anti-HGF antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-HGF antibodies in the treatment of esophageal and gastric cancer. | 2014-08-21 |
20140234329 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 2014-08-21 |
20140234330 | IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY - The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor E form a heteromeric receptor complex that is biologically active, and that IL-17C activity requires the IL-17RA-IL-17RE heteromeric receptor complex. Antagonists of the IL-17RA-IL-17RE heteromeric receptor complex are disclosed, as well as various methods of use. | 2014-08-21 |
20140234331 | HUMAN CTLA-4 ANTIBODIES AND THEIR USES - The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. | 2014-08-21 |
20140234332 | NOVEL HIV-2 ISOLATE - The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus. | 2014-08-21 |
20140234333 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases are therapeutically useful. | 2014-08-21 |
20140234334 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 - The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz | 2014-08-21 |
20140234335 | METHOD AND REAGENT FOR DIAGNOSIS AND/OR EVAULATION OF PROGRESSION OF GRAFT-VERSUS-HOST DISEASE - Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody. | 2014-08-21 |
20140234336 | Binding Molecule Having Influenza A Virus-Neutralizing Activity Produced from Human B Cell - The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention. | 2014-08-21 |
20140234337 | ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION - For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus. | 2014-08-21 |
20140234338 | THERAPEUTIC AGENT FOR USE IN A METHOD OF TREATING PSORIASIS OR ATOPIC DERMATITIS - The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti- | 2014-08-21 |
20140234339 | PEPTIDE OR ARRANGEMENT OF PEPTIDES FORMING A STAPHYLOCOCCUS AUREUS EPITOPE BINDING SITE - The invention concerns a peptide or arrangement of peptides forming a | 2014-08-21 |
20140234340 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO PLURALITY OF ANTIGEN MOLECULES REPEATEDLY - An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction. | 2014-08-21 |
20140234341 | ACUTE HEPATIC INSUFFICIENCY DEPRESSANT AND METHOD FOR EVALUATING DRUG EFFICACY THEREOF - The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF. | 2014-08-21 |
20140234342 | NKP46-MEDIATED NK CELL TUNING - The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like. | 2014-08-21 |
20140234343 | COMPOSITION FOR PREVENTION OR TREATMENT OF ISCHEMIC CARDIAC DISEASE, COMPRISING INHIBITOR AGAINST AGE-ALBUMIN SYNTHESIS OR RELEASE OF MONONUCLEAR PHAGOCYTE SYSTEM CELLS AS ACTIVE INGREDIENT - Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction. | 2014-08-21 |
20140234344 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2014-08-21 |
20140234345 | NOVEL ANTI-CANCER ISOCARBOSTYRIL ALKALOID CONJUGATES - The present application is directed to covalent conjugates between an isocarbostyril alkaloid and a lipophilic biomolecule, to pharmaceutical compositions comprising the conjugates and to therapeutic uses thereof, in particular for treating cancer. | 2014-08-21 |
20140234346 | PYRROLOBENZODIAZEPINES - A compound with the formula I: wherein: R | 2014-08-21 |
20140234347 | METHODS OF USING BIOMARKERS FOR PREDICTING THE OUTCOME OF AN IMMUNOTHERAPY AGAINST CANCER - The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods. | 2014-08-21 |
20140234348 | Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens - The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain. | 2014-08-21 |
20140234349 | NANOPARTICLES, PROCESS FOR PREPARATION AND USE THEREOF AS CARRIER FOR AMPHIPATIC AND HYDROPHOBIC MOLECULES IN FIELDS OF MEDICINE INCLUDING CANCER TREATMENT AND FOOD RELATED COMPOUNDS - The present invention regards nanoparticles comprising a sterol and a component derived from | 2014-08-21 |
20140234350 | OVARIAN CANCER VACCINES AND VACCINATION METHODS - Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines. | 2014-08-21 |
20140234351 | CANCER VACCINES AND VACCINATION METHODS - Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines. | 2014-08-21 |
20140234352 | B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 2014-08-21 |
20140234353 | METHODS OF OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided. | 2014-08-21 |
20140234354 | PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 2014-08-21 |
20140234355 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 2014-08-21 |
20140234356 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS - The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans. | 2014-08-21 |
20140234357 | H5 PROTEINS OF H5N1 INFLUENZA VIRUS FOR USE AS A MEDICAMENT - The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, wherein the H5N1 virus of a different clade comprises a particular polynucleotide and/or H5 protein. | 2014-08-21 |
20140234358 | NEWCASTLE DISEASE VIRUS VECTORED AVIAN VACCINES - The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease. | 2014-08-21 |
20140234359 | PLANT VIRAL VACCINES AND THERAPEUTICS - The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers. | 2014-08-21 |
20140234360 | INFLUENZA VACCINE - Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed. | 2014-08-21 |
20140234361 | NOVEL EXPRESSION VECTORS AND USES THEREOF - A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells. | 2014-08-21 |
20140234362 | DEFENSIN-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. | 2014-08-21 |
20140234363 | POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE - Polypeptides comprising non-typeable | 2014-08-21 |
20140234364 | TOTAL SYNTHESIS AND IMMUNOLOGICAL EVALUATION OF SACCHARIDE MOIETIES OF THE LIPOPOLYSACCHARIDE FROM NEISSERIA MENINGITIDIS - The present invention relates to the total chemical synthesis of the monosaccharide 35 | 2014-08-21 |
20140234365 | 2-HYDROXYHIPPURIC ACID ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE - The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label. | 2014-08-21 |
20140234366 | COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASE OR MAJOR DEPRESSIVE DISORDER (DEPRESSION) - The invention aims to provide a composition for treating atopic dermatitis, bronchial asthma, allergic rhinitis or major depressive disorder (depression), comprising a mixture of Formula antidoti coptidis (orengedokuto) and Formula repletionis animalis et supletionis medii (hochuekkito) or a mixture of Formula antidoti coptidis (orengedokuto) and Formula glycyrrhizae atractylodis cinnamomi hoelen (ryokeijutsukanto) as active components. Provided is a composition for preventing or treating an allergic disease or major depressive disorder, comprising a mixture of Formula antidoti coptidis (orengedokuto) and Formula repletionis animalis et supletionis medii (hochuekkito) or a mixture of Formula antidoti coptidis (orengedokuto) and Formula glycyrrhizae atractylodis cinnamomi hoelen (ryokeijutsukanto) as active components. | 2014-08-21 |
20140234367 | BOTANICAL FORMULATIONS - Disclosed is a topical skin composition, and methods for its use, that includes | 2014-08-21 |
20140234368 | HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES - Capsular saccharides derived from serogroups W135 and Y of | 2014-08-21 |
20140234369 | LIVE-ATTENUATED COMPOSITIONS FOR BACTERIAL INFECTIONS - The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity. | 2014-08-21 |
20140234370 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject. | 2014-08-21 |
20140234371 | MODIFIED GRAM POSITIVE BACTERIA AND USES THEREOF - The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or | 2014-08-21 |
20140234372 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 2014-08-21 |
20140234373 | Methods of Promoting Immune Tolerance - Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (IDO) enzyme activity in cells. The methods and compositions can be used to inhibit or reduce immune-mediated tissue destruction, to treat autoimmune diseases and inflammatory responses, to promote immune tolerance, to enhance tolerizing vaccines, to treat allergies, to treat asthma, or to enhance mucosal tolerance in subject. Methods and compositions for inducing a suppressive immune response for while minimizing undesirable side effects in the subject are also provided. An exemplary undesirable side effect is systemic release of INFγ. Exemplary compositions that can be used to induce an immune response in a subject without inducing systemic release of INFγ include compositions containing a polynucleotide lacking an immunostimulatory nucleic acid sequence complexed with a carrier. | 2014-08-21 |
20140234374 | COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC IMMUNITY - Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma). | 2014-08-21 |
20140234375 | Compositions and Methods for Eliciting an Immune Response to Escape Mutants of Targeted Therapies - Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response. | 2014-08-21 |
20140234376 | Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. | 2014-08-21 |
20140234377 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug. | 2014-08-21 |
20140234378 | Lobster hemolymph as a utility for treatment of mammalian tissue lesions - The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, | 2014-08-21 |
20140234379 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA - This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as | 2014-08-21 |
20140234380 | COMPOSITION FOR MANAGEMENT OF PERIODONTAL DISEASE - The composition for management of periodontal diseases includes a gel matrix having a polymer system and a plurality of microspheres dispersed in the polymer system. The polymer system contains about one-half a dose of medicament, while the microspheres contain the remainder. Upon administration of the composition into the periodontal cavity, the medicament in the polymer system provides an initial therapeutic benefit, while the remainder of the medication is released over time via degradation of the microspheres. This biphasic pattern of medicament delivery provides increased efficacy of the medicament through sustained delivery of the same. | 2014-08-21 |
20140234381 | SCAFFOLD FOR SUBRETINAL CELL TRANSPLANTATION AND DRUG DELIVERY - The following disclosure provides compositions and methods for the repairing of a diseased or disordered retina, for example, in patients suffering from age-related macular degeneration (AMD). | 2014-08-21 |
20140234382 | PEPTIDE NANOPARTICLES AND USES THEREFOR - The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin. | 2014-08-21 |
20140234383 | NON-AQUEOUS ORAL CARE COMPOSITIONS - The invention provides a non-aqueous oral care composition with a liquid continuous phase comprising a thickening agent, a humectant, and a crystalline structuring agent, characterised in that the composition further comprises abrasive amorphous silica particles which are capable of acting as a booster to the cleaning ability of the composition and which have a weight mean particle size (d50) ranging from 3 to 15 microns. Preferred components are carboxyvinyl polymers as thickening agent, glycerin as humectant and solid polyethylene glycols such as polyethylene glycol 3000 as structuring agent. The composition may further comprise a liquid polyethylene glycol. The composition has improved appearance (in particular shine or glossiness) and improved squeezability, i.e. good rheology, even at high temperatures (such as 40° C.). | 2014-08-21 |
20140234384 | LEAVE-ON COMPOSITIONS CONTAINING CELLULOSE MATERIALS - The compositions and methods of this invention relate to a leave-on skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 500 μm, a particle aspect ratio from about 2 to about 25 and an average thickness of from about 1 to about 500 μm; and a cosmetically acceptable carrier. | 2014-08-21 |
20140234385 | ANTIVIRAL MATERIAL, ANTIVIRAL FILM, ANTIVIRAL FIBER, AND ANTIVIRAL PRODUCT - In one embodiment, an antiviral material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide composite microparticles. The microparticles have an inactivation effect R of 1 or more expressed by [R=log C−log A], when there is evaluated a virus titer by inoculating on a specimen to which the microparticles are adhered, at least one virus selected from a low pathogenic avian influenza virus (H9N2), a high pathogenic avian influenza virus (H5N1) and a swine influenza virus, and irradiating the specimen with visible light having a wavelength of 380 nm or more and illuminance of 6000 lx. for 24 hours. | 2014-08-21 |
20140234386 | MINERAL FEED-THROUGH FORMULATION - The present invention provides feed-through pesticide formulation suitable for hydrophobic active ingredients. The formulation comprises a hydrophobic active ingredient on a solid carrier, with a hydrophilic coating and an optional hydrophobic coating contacting the hydrophilic coating. | 2014-08-21 |
20140234387 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2014-08-21 |
20140234388 | BIOSCAFFOLDS FOR FORMATION OF MOTOR ENDPLATES AND OTHER SPECIALIZED TISSUE STRUCTURES - Provided herein are scaffolds and methods useful to promote the formation of functional clusters on a tissue, for example, motor endplates (MEPs) or a component thereof on skeletal muscle cells or tissue, as well as the use of scaffolds so produced for repairing a tissue injury or defect. | 2014-08-21 |
20140234389 | SUSTAINED DRUG DELIVERY IMPLANT - Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration. | 2014-08-21 |
20140234390 | SUSTAINED DRUG DELIVERY IMPLANT - Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration. | 2014-08-21 |
20140234391 | LOCATION-SPECIFIC BACTERIAL MANAGEMENT - A method for reducing the population of pathogenic bacteria in an animal being reared in an animal rearing facility is provided. The method involves using one or more than one naturally-occurring location-specific bacteriophages selected to be highly specific to the strains of the one or more than one pathogen present in the facility, a phage component derived from the one or more than one naturally-occurring location-specific bacteriophages, or a combination thereof, to produce a location-specific bacteriophage preparation. The preparation is administered to the animal, to reduce the one or more than one pathogenic bacteria. The method may also involve a step of identifying location-specific isolates of the one or more than one pathogenic bacteria at or near the animal rearing facility. | 2014-08-21 |
20140234392 | PHYSICALLY AND CHEMICALLY STABLE NICOTINE-CONTAINING PARTICULATE MATERIAL - A nicotine-containing particulate material for release of nicotine, the material comprising a combination of nicotine or a pharmaceutically acceptable salt, complex or solvate thereof and a microcrystalline cellulose, The particulate material is stable upon storage and releases nicotine relatively fast. The particulate material can be used in the manufacture of nicotine-containing pharmaceutical composition, wherein the release of nicotine can be designed to be relatively fast so as to obtain a fast onset of action. | 2014-08-21 |
20140234393 | ADHESIVE PATCH - Provided is an adhesive patch which has excellent rivastigmine storage stability and an increased skin permeability of rivastigmine to such an extent that the amount of percutaneous absorption required for treating Alzheimer's disease is obtained. | 2014-08-21 |
20140234394 | BENEFICAL CONTACT SURFACES FOR FUNCTIONAL OBJECTS - An enhanced article which has a beneficial contact surface intended to allow bioabsorption of beneficial materials through the user's contact with the enhanced article in use. A functional or ornamental article which has at least one contact surface intended to come in contact with a human user includes a beneficial contact surface for covering the article's contact surface and providing a beneficial surface contact compound adapted to come in contact with a human user touching the article. The beneficial contact surface is connected to the article so that the contact surface of the article is covered by the beneficial contact surface. The presence of the beneficial surface contact compound in the beneficial contact surface means results in the exposure of the user's skin to the beneficial surface contact compound to allow absorption by the user. The article can be any functional or ornamental object which in its regular use comes in contact with a user's skin, including but not limited to such objects as a cellphone, doorknob, packaging, clothing, brushes, laptops and shower curtains. Also, a process by which articles can be converted into enhanced articles through addition of a beneficial contact surface which provides bioabsorption of beneficial materials added as contact surfaces for the articles through various techniques. | 2014-08-21 |
20140234395 | PLASTER HAVING ADJUSTABLE OCCLUSION - Transdermal or topical plasters containing active ingredient are provided that include a non-occlusive back layer, a matrix formed from of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, in which the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers. | 2014-08-21 |
20140234396 | EXTERNAL PATCHES CONTAINING ETOFENAMATE - The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. | 2014-08-21 |
20140234397 | TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded. | 2014-08-21 |
20140234398 | Dissolution of Arterial Plaque - Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation. | 2014-08-21 |
20140234399 | HIV VACCINE - The present invention relates to immunogenic compositions comprising HIV-1 antigens and uses thereof in the prevention and/or treatment of HIV-1. In particular, the invention relates to the use of HIV-1 antigens from one clade in the prevention and/or treatment of disease associated with HIV-1 infection from a heterologous HIV-1 clade. | 2014-08-21 |
20140234400 | Targeted Lipid-Drug Formulations for Delivery of Drugs to Myeloid and Lymphoid Immune Cells - A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a T-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent. The other cell type that is infected with or susceptible to infection with an infectious agent may belong to a malignant tumor or a part of the immune system contributing to the development, maintenance, or exacerbation of an autoimmune disease or chronic inflammatory disease. | 2014-08-21 |
20140234401 | METHOD OF TREATING INFLAMMATION USING HUMAN IMMUNOSUPPRESSIVE PROTEIN - A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (HISP) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hNT cell culture. The immunosuppressant protein has a molecular weight of about 40-100 kDa, an isoelectric point of about 4.4, a net ionic charge and is capable of suppressing T-cell activation, T-cell proliferation and the production of IL-2. This protein can be used in treating inflammation, preventing graft rejection after transplantation, treating autoimmune diseases and suppressing allergic responses as well as other uses. | 2014-08-21 |
20140234402 | Intravenous Infusion of Curcumin and a Calcium Channel Blocker - Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers. | 2014-08-21 |
20140234403 | LIPOSOME PRODUCTION USING ISOPROPANOL - Provided are compositions and methods for producing a lipidic film. The method comprises the steps of: (i) dissolving a lipid mix in isopropanol to form a homogeneous mix; and (ii) removing the solvent from the homogeneous mix to form a lipidic film, wherein the lipid mix comprises a lipid and cholesterol. | 2014-08-21 |
20140234404 | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof - The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response. | 2014-08-21 |
20140234405 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT - To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes. | 2014-08-21 |
20140234406 | NOVEL NANOPARTICULATE SUSPENSION FOR INCORPORATING FAT-SOLUBLE VITAMINS IN THE TREATMENT OF HAIR THINNING and HAIR LOSS - The present invention provides novel compositions comprising a nutritional supplement containing vitamin D-3 (cholecalciferol) and other supporting nutrients (i.e., fat-soluble vitamins A and E) to be administered orally via capsules to human subjects for the prophylaxis and mitigation of hair thinning and hair loss in both men and women. Colloidal silicon dioxide functions to form a nanoparticulate suspension and acts as a viscosifier to thicken the oil(s) used in the capsule filling operation. The colloidal silica contains silicon which acts as a nutrient to help strengthen existing hair, and also functions as a microencapsulation agent, which can incorporate vitamins A and E into its porous structure by sonication. | 2014-08-21 |
20140234407 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance - The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely. | 2014-08-21 |
20140234408 | BEVERAGE COMPOSITIONS AND OTHER FORMULATIONS FOR TREATING ALLERGIES AND METHODS FOR MAKING THE SAME - A composition for preventing and/or alleviating an allergy related condition and methods of making such compositions are disclosed herein. A composition in accordance with a particular embodiment can include honey having pollen derived from a known plant species and/or from a known geographic location. The composition can also include a herbal and/or vitamin supplement, wherein the supplement has an anti-inflammatory property. The composition can be in liquid form, such as suitable for drinking, or in a powdered form suitable for reconstitution in liquid. | 2014-08-21 |
20140234409 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF - The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment. | 2014-08-21 |
20140234410 | COMBINATION PRODUCTS - A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active ingredient, and at least some of the minicapsules containing a corticosteroid as another active ingredient. | 2014-08-21 |
20140234411 | SEAMLESS CAPSULE AND MANUFACTURING METHOD THEREFOR - The present invention is related to a seamless capsule which easily dissolves in the oral cavity etc. The present invention provides a seamless capsule comprising a capsule content solution, and a capsule shell enclosing the capsule content solution, wherein the capsule shell comprises a gelatin having a bloom value of 50 to 190 and wherein the seamless capsule has a capsule shell-dissolution time of 60 seconds or less when the dissolution time is determined by a disintegration test using water as a test solution. | 2014-08-21 |
20140234412 | ORAL COMPOSITIONS - Suggested are new compositions for oral ingestion, comprising at least one active agent from the group of alkamides. The compositions which are orally ingested reduce the uptake of free fatty acids in the adipocytes and at the same time stimulate the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. In doing so, the new compositions are thus perfectly suitable to counteract any undesired gain of weight. | 2014-08-21 |
20140234413 | CAGED PLATINUM NANOCLUSTERS FOR ANTICANCER CHEMOTHERAPEUTICS - A caged platinum nanocluster complex is disclosed. The complex comprises (a) an amine-terminated dendrimer; and (b) a platinum nanocluster comprising platinum oxides, the platinum nanocluster being confined inside of the amine-terminated dendrimer. The complex exhibits cytotoxicity to cancer cells. A double-caged platinum nanocluster complex is also disclosed, which comprises polyethylene glycol (PEG) coated on the surface of a dendrimer caged platinum nanocluster complex. The double-caged caged platinum nanocluster complex comprises pH-sensitive bonds on the surface thereof. Also disclosed are methods of preparing and using the same. | 2014-08-21 |
20140234414 | Novel Dosage Form - There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration. | 2014-08-21 |
20140234415 | Tablet Dosage Forms - The present invention features tablet dosage forms comprising two or more different active ingredients. In one embodiment, a tablet dosage form of the invention comprises a first layer and a second layer, wherein the first layer comprises polymer-based solid dispersion particles having a mean particle size of no more than 200 μm. | 2014-08-21 |
20140234416 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 2014-08-21 |